<?xml version='1.0' encoding='utf-8'?>
<document id="29736825"><sentence text="Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation."><entity charOffset="50-58" id="DDI-PubMed.29736825.s1.e0" text="warfarin" /></sentence><sentence text="The aim of this study was to estimate the proportion of bleedings that occurred among warfarin users attributable to the concomitant use of other medications" /><sentence text=" A general approach for measuring the impact of the prescriptive inappropriateness on drug adverse outcomes at the population level is described" /><sentence text="" /><sentence text="A meta-analysis was conducted to obtain summary relative risks of bleeding associated with concurrent use of warfarin and other medications compared to warfarin use alone" /><sentence text=" A population-based investigation was performed, in an Italian cohort of cardiopathic patients aged 65Â years or older, to estimate the prevalence of concurrent users of warfarin and other medicaments"><entity charOffset="169-177" id="DDI-PubMed.29736825.s6.e0" text="warfarin" /></sentence><sentence text=" The population attributable fraction was computed by combining data on summary relative risks and prevalence of concurrent users" /><sentence text="" /><sentence text="Concomitant use of warfarin and cotrimoxazole, amiodarone, quinolones, macrolides, platelet aggregation inhibitors, SSRIs, NSAIDs, and lipid-lowering agents was associated with an increased risk of bleeding"><entity charOffset="19-27" id="DDI-PubMed.29736825.s9.e0" text="warfarin" /><entity charOffset="32-45" id="DDI-PubMed.29736825.s9.e1" text="cotrimoxazole" /><entity charOffset="47-57" id="DDI-PubMed.29736825.s9.e2" text="amiodarone" /><entity charOffset="59-69" id="DDI-PubMed.29736825.s9.e3" text="quinolones" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e0" e2="DDI-PubMed.29736825.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e0" e2="DDI-PubMed.29736825.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e0" e2="DDI-PubMed.29736825.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e0" e2="DDI-PubMed.29736825.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e1" e2="DDI-PubMed.29736825.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e1" e2="DDI-PubMed.29736825.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e1" e2="DDI-PubMed.29736825.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e2" e2="DDI-PubMed.29736825.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29736825.s9.e2" e2="DDI-PubMed.29736825.s9.e3" /></sentence><sentence text=" The corresponding attributable fractions were 3% (95% CI 2 to 4%), 21% (1 to 41%), 21% (17 to 25%), 9% (8 to 10%), 14% (12 to 16%), 6% (5 to 8%), 10% (1 to 20%), and 8% (0 to 18%), respectively" /><sentence text="" /><sentence text="More than half of bleeding events occurring among frail elderly using warfarin are attributable to a concomitant use of warfarin with certain drugs" /><sentence text=" Because some of these drugs appear to be essential for the treatment/prevention of cardiovascular conditions, and their concomitant use with warfarin could be acceptable in some cases, proper INR-monitoring and warfarin dose adjustments are requested" /><sentence text="" /></document>